EVFM
Evofem Biosciences, Inc.0.0100
-0.0010-9.09%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.27MP/E (TTM)
-Basic EPS (TTM)
-0.05Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
Merger terminated by shareholder vote
Evofem Biosciences terminated its merger agreement with Aditxt on October 20, 2025, after shareholders rejected the deal at a special meeting, with 93.2 million votes for but 7.2 million against among 100.5 million cast. No termination fees were paid, ending ancillary pacts except a 2023 NDA. The company now pivots to regaining national stock listing and raising growth capital to hit positive EBITDA in 2027. Merger fallout risks litigation and partner retention.
8-K
Evofem amends note maturity
Evofem Biosciences amended its securities purchase agreement with Adjuvant funds on October 13, 2025, setting a new six-month maturity for the outstanding convertible promissory notes. This shortens the repayment timeline while prohibiting prepayment without Adjuvant's consent, unless triggered by a change of control or acceleration. The move tightens debt terms. No financial amounts disclosed.
BSEM
BioStem Technologies, Inc.
3.84-0.11
CASI
CASI Pharmaceuticals, Inc.
0.88+0.01
DARE
Dare Bioscience, Inc.
2.26-0.02
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ENVB
Enveric Biosciences, Inc.
5.24-0.12
EPIX
ESSA Pharma Inc.
0.20+0.00
EVGN
Evogene Ltd.
1.04+0.00
EVOK
Evoke Pharma, Inc.
11.00+0.04
FEMY
Femasys Inc.
0.85-0.01
PHGE
BiomX Inc.
1.55-0.18